Detection of EGFR mutations in circulating tumor (ct) DNA from plasma samples can be accomplished using the cobas platform, according to findings presented by Kumar et al at the 2017 European Lung Can...
An investigation of immune cell subtypes in the tumor microenvironment of patients with lung adenocarcinoma and squamous cell carcinoma (SCC) identified an immune subgroup that associates with prolong...
Ensartinib demonstrated intracranial responses in patients with anaplastic lymphoma kinase (ALK)–positive non–small cell lung cancer (NSCLC) and central nervous system (CNS) metastases, ac...
Validation using patient data of an outcome prediction model for the development of dyspnea subsequent to radiotherapy revealed that the prognostic factors in the model did not adequately predict for ...
A late-breaking subanalysis of the phase III CONVERT trial presented by Gomes et al at the 2017 European Lung Cancer Conference (ELCC) shows that white blood cell–boosting drugs are safe during ...
Some patients with advanced lung cancer benefit from immunotherapy, even after the disease has progressed as evaluated by standard criteria, according to research presented by Artal-Cortes et al at th...
White blood cell counts may predict whether patients with lung cancer will benefit from immunotherapy, according to research presented by Tiseo et al at the 2017 European Lung Cancer Conference (...
Osimertinib (Tagrisso) improved cancer-related symptoms in patients with advanced lung cancer, according to an analysis of patient-reported outcomes from the AURA3 phase III clinical trial presented b...
Men may need more frequent lung cancer screening than women, according to research to be presented by Koo et al at the 2017 European Lung Cancer Conference (ELCC). The U.S. Preventive Services Task F...
Patients with lung cancer treated with programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) checkpoint inhibitors may be at increased risk of adverse events after receiving the ...